Abstract:Objective To evaluate the efficacy and safety and to analyze related complications and potential prognostic factors of allogeneic hematopoietic stem cell transplantation(allo-HSCT ) on hematological malignancies .Methods Patients with hemato-logical malignancies who underwent allo-HSCT from June 2010 to June 2015 were investigated in this retrospective study .Accord-ing to the donor types ,it was divided into compatriots sibling-matched transplantation group (n = 52) and haploid transplantation group (n= 98) .The preconditioning regimens were busulfan/cyclophosphamide ,and anti-thymocyte globulin were needed in haploid transplantation group .Short-term methotrexate + cyclosporine A + mycophenolate mofetil were used for prevention of graft-ver-sus-host disease .The efficacy and safety and related complications of allo-HSCT were analyzed .Results All patients achieved full donor type engraftment ,which was identified by blood type ,chromosome test and DNA polymorphism .The mean times of neutro-phil and platelet engraftment were 12 d and 16 d in compatriots sibling-matched transplantation group and 13 d and 16 d in haploid transplantation group ,respectively .59 cases (39 .3% ) patients were oral mucosa ulcer ,47 patients (31 .3% ) were bacteria and/or fungal infection ,41 cases (27 .3% ) patients were CMV infection ,48 cases (32 .0% ) were acute GVHD ,43 patients (28 .7% ) were chronic GVHD .The median follow-up time of 23 months (1 - 60 months) ,115 patients (76 .7% ,115/150) were disease-free sur-vival ,including 38 cases (73 .1% ,38/52) in compatriots sibling-matched transplantation group ,77 cases (78 .6% ,77/98) in haploid transplantation group ;35 cases (23 .3% ,35/150) patients were died ,including 14 cases (26 .9% ,14/52) in compatriots sibling-matched transplantation group ,21 cases (21 .4% ,21/98) in haploid transplantation group .Death cause analysis showed that 12 ca-ses (8 .0% ) complications from transplantation related death ,of which 5 cases (3 .3% ) were severe infection ,7 cases (4 .7% ) caused by acute GVHD ,23 cases (8 .7% ) patients died because of the primary disease recurrence .The survival rate and mortality was similar between the two groups (P> 0 .05) .Conclusion Allo-HSCT is safe and effective treatment in hematological malignan-cies .The curative effect and security with haploid transplantation were similar to compatriots sibling-matched transplantation .It is necessary to prevent prognostic impact factors such as acute GVHD and infection early .

Efficacy of Activated Haploidentical Allogeneic Hematopoietic Stem Cells on Advanced Intractable Carcinoma

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

Therapeutic Effect of Haploidentical Peripheral Blood Stem Cell Treatment on Relapsed/refractory Ovarian Cancer.

[Salvage Trerapy for Patients with Relapsed and Refractory Lymphoma by Allogeneic Hematopoietic Stem Cell Transplantation].

[Outcome of Haploidentical Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma].

Safety and efficacy of allogeneic hematopoietic stem cell transplantation in R/R B-NHL patients with disease progression after CAR-T therapy

Efficacy of Hematopoietic Stem Cell Transplantation in the Treatment of 110 Cases Hematologic Malignancies

Curative effect analysis of allogeneic hematopoietic stem cell transplantation for 150 patients with hematological malignancies

[Evaluation of Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/refractory Peripheral T-cell Lymphoma with Chemoresistance].

Clinical Study on Haploid HLA-haploidentical Hematopoietic Stem Cell Transplantation for Treatment of Malignant Hematological Disease

Antitumor Effect Of Large Doses Il-2-Activated Hla Haploidentical Peripheral Blood Stem Cells On Refractory Metastatic Solid Tumor Treatment

[Treatment of 30 Elderly Patients with Advanced Myeloid Neoplasm by Allogeneic Hematopoietic Stem Cell Transplantation].

Clinical Treatment of Malignant Lymphoma by Autologous Hematopoietic Stem Cell Transplantation in 40 Patients

[Therapeutic Effect of Allogeneic Hematopoietic Stem Cell Transplantation with Reduced-Intensity Conditioning Regimens on Hematological Malignancies].

Advanced and Recurrent Malignant Lymphoma Were Treated by BEAC Regimen Supported with Autologous Hemotopoietic Stem Cells Transplantation

The Superiority of Haploidentical Related Stem Cell Transplantation over Chemotherapy Alone As Postremission Treatment for Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in First Complete Remission.

[Clinical Efficacy of Autologous Hematopoietic Stem Cell Transplantation Using Tumor-ablative Conditioning Regimen for Patients with Refractory/Relapsed Non-Hodgkin's Lymphoma].

Haploidentical Hematopoietic Stem Cell Transplantation Without In Vitro T-Cell Depletion For The Chronic Myeloid Leukemia: Improved Outcomes In Patients With Accelerated Phase And Blast Crisis Phase

Effect of Granulocyte Macrophage Colony-Stimulating Factor Combined with Allogeneic Cellular Immunotherapy for Advanced Cancer

Effect Comparison Between Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Patients of Aggressive Non-Hodgkin′s Lymphoma

Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation]